Drug design and development. A realistic appraisal
- 1 January 1978
- journal article
- editorial
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 21 (1) , 1-4
- https://doi.org/10.1021/jm00199a001
Abstract
The discovery of new biologically-therapeutically active structures continues to depend on screening and isolated observations of unexpected drug metabolites and drug activities. The selection of therapeutically improved and useful chemicals requires molecular modification. Refinements in intuitive and physicochemical methodology can provide shortcuts in random choices and permit extrapolations of some facets of activity with a variable degree of accuracy. The final decisions concerning the usefulness of a drug remain in the domain of experimental and clinical pharmacology.This publication has 7 references indexed in Scilit:
- Bioactivation as a Model for Drug Design Bioreductive AlkylationScience, 1977
- Quantitative structure-activity relationships. 1. The modified Free-Wilson approachJournal of Medicinal Chemistry, 1976
- Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson analysisJournal of Medicinal Chemistry, 1976
- Estrogen Receptor in the Mammalian LiverScience, 1976
- STRUCTURAL BASIS FOR INHIBITION OF PROTEIN SYNTHESIS BY EMETINE AND CYCLOHEXIMIDE BASED ON AN ANALOGY BETWEEN IPECAC ALKALOIDS AND GLUTARIMIDE ANTIBIOTICSProceedings of the National Academy of Sciences, 1966
- Metabolic studies of allopurinol, an inhibitor of xanthine oxidaseBiochemical Pharmacology, 1966
- USE OF MOLECULAR ORBITAL CALCULATIONS AS AN AID TO CORRELATE STRUCTURE AND ACTIVITY OF CHOLINESTERASE INHIBITORS1965